1. Current practice patterns across Europe with regard to the use of antithrombotic treatment in end-of-life care of cancer patients (Time Frame - 7 days): The main analysis of the FMR will be descriptive. Responses to the Discrete Choice Experiments will be used to generate preference coefficients for each level (e.g., high/low) of each attribute (e.g., bleeding risk)
2. Relevance of patient's age for the decision on continuation or discontinuation of antithrombotic therapyin cancer patients during end-of-life care (Time Frame - 7 days)
3. Relevance of patient's prognosis for the decision on continuation or discontinuation of antithrombotic therapyin cancer patients during end-of-life care (Time Frame - 7 days)
4. Relevance of patient's performance status (Eastern Cooperative Oncology Group (Time Frame - 7 days): (ECOG)) for the decision on continuation or discontinuation of antithrombotic therapy
5. Relevance of patient's type of antithrombotic medication for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
6. Relevance of patient's indication for antithrombotic medication for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
7. Relevance of patient's thrombotic risk for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
8. Relevance of patient's bleeding risk for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
9. Relevance of patient's symptom burden for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
10. Relevance of patient's medication burden for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
11. Relevance of patient's preference (pro/contra continuation) for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
12. Relevance of physician's experience (with deprescribing) for antithrombotic medication for the decision on continuation or discontinuation of antithrombotic therapy (Time Frame - 7 days)
Physician survey on antithrombotic medication during end-of-life care in cancer patients: Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., "Have you ever considered deprescribing antithrombotic medicine"?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.
For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.
Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!
